GGT is regulated by medical ozone in patients with RA and OA, and is a marker of the patient’s response to treatment [29,30]; it is activated by oxidants and is associated with Nrf2-mediated signaling mechanisms [31]. This evidence concerns the gene NFE2L2 and rheumatoid arthritis.